A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $147 to $220
Optimistic Buy Rating for Jazz Pharmaceuticals Amidst Short-term Challenges and Long-term Growth Potential
RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $172
A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $166 to $216
Analysts Conflicted on These Healthcare Names: Spyre Therapeutics (SYRE), Fresenius Medical Care (FMS) and Jazz Pharmaceuticals (JAZZ)
Jazz Pharmaceuticals Analyst Ratings
Piper Sandler Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Vera Therapeutics (VERA) and Dexcom (DXCM)
Optimistic Buy Rating for Jazz Pharmaceuticals Amid Growth Prospects and Strategic Positioning
RBC Capital Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $182
Jazz Pharmaceuticals (JAZZ) Gets a Buy From RBC Capital
TD Cowen Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $205
Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $210
Jazz Pharmaceuticals Price Target Maintained With a $210.00/Share by Needham
Jazz Pharmaceuticals Analyst Ratings
UBS Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Cuts Target Price to $166
RBC Capital Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Raises Target Price to $182
RBC Raises Price Target on Jazz Pharmaceuticals to $182 From $178, Keeps Outperform Rating
Jefferies Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $183
BofA Securities Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $213